

Synthesis and Biological Evaluation of Pyranone Analogues of Territrem B

Xiang Rui JIANG¹, Lei AO¹, Chang Xin ZHOU¹, Lei Xiang YANG¹, Hai Bo LI¹,
Xiu Mei WU², Hua BAI², Qi Jun ZHANG¹, Yu ZHAO^{1*}

¹ Department of Traditional Chinese Medicine and Natural Drug Research, College of
Pharmaceutical Sciences, Zhejiang University, Hangzhou 310031

² Zhejiang Hisun Naturelite Pharmaceutical R&D Co., Ltd., Hangzhou 310006

Abstract: 23 compounds containing pyranone pharmacophore of territrem B were designed and synthesized. Some of the analogues showed IC₅₀ values of AChE inhibition at 10⁻⁵ mol/L.


Keywords: 2H-Pyran-2-one, territrem B, synthesis, AChE inhibitor.

As a highly selective and potent acetylcholinesterase (AChE) inhibitor, territrem B was isolated by Ling *et al.* from a strain of *Aspergillus terreus* in 1979^{1,2}. Zhao *et al.* reported mimic preparation of territrem B analogues from triterpenoids and found that the enone moiety and aromatic ring played important roles in their synthetic compounds^{3,4}. To further detect essential pharmacophors for AChE inhibitors, we simplified the A/B ring system of territrem B and synthesized a number of pyranone pharmacophore derivatives, including 3-N-aminomethyl-6-substituted phenyl-2H-pyran-2-one **9** and 3-O-hydroxymethyl-6-substituted phenyl-2H-pyran-2-one **10**.

The synthetic route started from ethyl acetoacetate **1**, which was reacted with iodomethane to give ethyl 2-methylacetoacetate **2** (**Scheme 1**). The resulted **2** was condensed with 3,4-dimethoxybenzaldehyde to afford **3**, which was reduced to a diol **4**. **4** was then subjected to hydrolysis to give an acid **5**. Intramolecular esterification of **5** provided tetrahydro- α -pyrone **6**. This step could be carried out *via* two different methods. Esterification catalyzed by *p*-toluenesulfonic acid provided 31% yield of **6**, while esterification catalyzed by dicyclohexylcarbodiimide (DCC) and 4-dimethylamino-pyridine (DMAP) could promote the yield to 61%. Two paths (path A and path B) were performed to prepare the dihydro-2H-pyran-2-one **7** (**Scheme 1**). In path A, **6** was reacted with mesyl chloride then treated with 1,8-diazacyclo[5.4.0]undec-7-ene (DBU) at room temperature to provide a dihydropyranone **7** in a 47% yield. In path B, the hydroxyl was directly eliminated under the catalysis of *p*-toluenesulfonic acid to provide **7** with a lower yield (*ca.* 35%).

* E-mail: dryuzhao@zju.edu.cn, or dryuzhao@hotmail.com

Scheme 1




Reagents and conditions: a) MeI, Na, EtOH, reflux, 56%; b) 3,4-dimethoxybenzaldehyde, NaH, *n*-BuLi, THF, -20°C, 72%; c) NaBH₄, MeOH, 0°C; d) 1 mol/L LiOH, EtOH, rt.; e) HCl, H₂O; f) *p*-TsOH, THF, rt., 4 steps total yield 35%; or DCC, DMAP, CH₂Cl₂, rt., 4 steps total yield 64%; path A: g) MsCl, Et₃N, CH₂Cl₂, 0°C; h) DBU, toluene, rt., 47% in two steps; path B: i) *p*-TsOH, THF, 50-60°C, 35%; j) NBS, AIBN, CCl₄, 44%; k) RNH₂ or R(R')NH (for **9o**, **9p** and **9r**), MeCN, rt.; l) K₂CO₃, Me₂CO, ROH, rt.

The bromide **8** was then obtained by reaction of **7** with N-bromosuccinimide (NBS) and 2,2-azobisisobutyronitrile (AIBN) in carbon tetrachloride. It was quite interesting that this step not only induced bromination on the 4-methyl and C-2' of aromatic ring, but also accelerated an elimination of the dihydropyran-2-one to a pyran-2-one. According to the analysis of the by-products of this bromination reaction at different temperatures, it could be deduced that the bromination first happened on the aryl part before occurring on the 3-methyl and C-6 methine to form a tribromide **7a** as an unstable intermediate (**Scheme 1**). The bromine hydride molecule was then eliminated from C-5 and C-6 to form the dibromide **8**, which was reacted with different amines or different substituted phenols to give the corresponding derivatives of **9** and **10** (**Table 1** and **Table 2**).

Table 1 Structures of compounds 9a-r and 10a-e

Compd.	R	R'	Compd.	R	R'	Compd.	R	R'
9a		H	9i		H	9q		H
9b		H	9j		H	9r*	/	/
9c		H	9k		H	10a		/
9d		H	9l		H	10b		/
9e		H	9m		H	10c		/
9f		H	9n		H	10d		/
9g		H	9o*	/	/	10e		/
9h		H	9p*	/	/			

* For compounds 9o, 9p and 9r, the structures are:



All of the synthesized pyranone analogues of territre B were evaluated on their AChE inhibitory activities. It was found that 9r exhibited an IC₅₀ of 7.2×10⁻⁵ mol/L and compounds 9p and 9e also showed inhibitory potency at 10⁻⁵ mol/L scale. These inhibitory activities suggested that the pyranone moiety is perhaps another pharmacophor for AChE inhibition.

Table 2 The m.p. and yields of **9a-r** and **10a-e**

Compd.	mp (°C)	yield (%)	Compd.	m.p. (°C)	yield (%)	Compd.	m.p. (°C)	yield (%)
9a	105-108	47.6	9i	160-161	11.1	9q	/ [*]	76.2
9b	129-131	76.2	9j	66-68	35.9	9r	203-205	88.5
9c	138-141	69.0	9k	/ [*]	35.7	10a	140-142	64.4
9d	70-73	75.6	9l	108-109	35.9	10b	204-205	79.6
9e	/ [*]	50.0	9m	143-145	11.6	10c	148-151	84.7
9f	35-37	56.6	9n	110-113	12.0	10d	181-182	55.6
9g	113-114	<10.0	9o	109-112	83.3	10e	/ [*]	40.6
9h	157-159	20.5	9p	93-94	73.3			

*. “/” implies that corresponding compound is colorless gem.

Acknowledgments

The authors are grateful to Dr. Xiaojiang Hao and Prof. Shoen-Sheng Lee for their encouragement on this research topic. We thank Junjun Xu for technical assistances. The authors appreciate Dr. F. Guéritte and Prof. J. Stöckigt for useful discussions. One of the authors (Y. Zhao) would also like to express his thanks to the Chinese Ministry of Education as well as to Mr. Ka-shing Li for the “Cheung Kong Professorship” at Zhejiang University.

References and Notes

1. K. H. Ling, C. K. Yang, F. T. Peng, *Appl. Environ. Microbiol.*, **1979**, *37*, 355.
2. K. H. Ling, H. H. Liou, C. M. Yang, C. K. Yang, *Appl. Environ. Microbiol.*, **1984**, *47*, 98.
3. Y. Zhao, Y. L. Ku, X. J. Hao, S. S. Lee, *Tetrahedron*, **2000**, *56*, 8901.
4. J. Zhao, F. Zhao, Y. Wang, *et al.*, *Helv. Chim. Acta*, **2004**, *87*, 1832.
5. Selected data of compounds: **9a**. puff powder; ¹H NMR (400 MHz, CDCl₃, δ ppm): 3.93 (s, 3H, 4'-OMe), 3.95 (s, 3H, 5'-OMe), 4.25 (s, 2H, H-7), 6.64 (d, 2H, *J*=8.0 Hz, H-2'', H-6''), 6.78 (t, 1H, *J*=7.6 Hz, H-4''), 6.94 (d, 1H, *J*=8.8 Hz, H-5), 7.22 (dd, 2H, *J*=8.4, 8.0 Hz, H-3'', H-5''), 7.34 (s, 1H, H-6'), 7.49 (d, 1H, *J*=8.8 Hz, H-4), 7.49 (s, 1H, H-3'); MS (ESI) *m/z* 416 (M+1)⁺. **9b**. puff powder; ¹H NMR (400 MHz, CDCl₃, δ ppm): 3.76 (s, 3H, 4''-OMe), 3.93 (s, 3H, 4'-OMe), 3.95 (s, 3H, 5'-OMe), 4.21 (s, 2H, H-7), 6.65 (d, 2H, *J*=8.8 Hz, H-3'', H-5''), 6.82 (d, 2H, *J*=8.8 Hz, H-2'', H-6''), 6.94 (d, 1H, *J*=8.8 Hz, H-5), 7.34 (d, 1H, *J*=2.0 Hz, H-6'), 7.49 (dd, 1H, *J*=8.8, 2.0 Hz, H-4), 7.50 (s, 1H, H-3'); MS (ESI) *m/z* 446 (M+1)⁺. **9c**. puff powder; ¹H NMR (400 MHz, CDCl₃, δ ppm): 3.93 (s, 3H, 4'-OMe), 3.95 (s, 3H, 5'-OMe), 4.23 (s, 2H, H-7), 6.57 (d, 2H, *J*=9.2 Hz, H-2'', H-6''), 6.93 (d, 1H, *J*=8.4 Hz, H-5), 7.17 (d, 2H, *J*=9.2 Hz, H-3'', H-5''), 7.34 (d, 1H, *J*=2.0 Hz, H-6'), 7.45 (s, 1H, H-3'), 7.51 (dd, 1H, *J*=8.4, 2.0 Hz, H-4); MS (ESI) *m/z* 450 (M+1)⁺. **10a**. colorless amorphous powder; ¹H NMR (400 MHz, CDCl₃, δ ppm): 3.79 (s, 3H, 4''-OMe), 3.94 (s, 3H, 4'-OMe), 3.96 (s, 3H, 5'-OMe), 4.92 (s, 2H, H-7), 6.88 (d, 2H, *J*=9.2 Hz, H-3'', H-5''), 6.95 (m, 3H, H-2'', H-6'', H-5), 7.26 (s, 1H, H-6'), 7.52 (dd, 1H, *J*=6.8, 1.6 Hz, H-4), 7.73 (s, 1H, H-3'); MS (ESI) *m/z* 447 (M+1)⁺.

Received 12 November, 2004